In this episode, we discuss ketamine as a rapid-acting treatment for depression, potentially helping the brain to heal itself, and investigations of ketamine as a treatment for anxiety and PTSD. We dive deep into the mechanisms of ketamine’s neuroplastic potential in the brain what it means for the future of therapy.
The advent of GLP-1 receptor agonists, such as semaglutide (marketed as Ozempic and Wegovy), has brought promising prospects for weight loss and overall metabolic health improvement (Kim & Kim, 2020). These medications have demonstrated their effectiveness in shedding unwanted pounds and potentially enhancing cardiovascular and metabolic well-being. However, this scientific inquiry delves into a pertinent concern: does the pursuit of weight loss through these pharmacological interventions come at the expense of one’s invaluable muscle mass (Srikanthan & Karlamangla, 2014)? This article will examine the current body of evidence on the impact of GLP-1 receptor agonists on muscle mass and strength, shedding light on whether these benefits indeed come with a price (Ashtary-Larky et al., 2020).
In less than a century, human diets have transformed in ways that our distant ancestors could not have imagined. Although it is doubtful that humankind had an identifiable “ancestral” diet, the transition of our diets from whole and minimally processed foods to energy abundance and highly refined foods represents a dramatic shift in eating patterns. …
How do drugs like Ozempic (semaglutide) cause weight loss? What happens when someone comes off of these drugs? In this episode, we discuss how these drugs (GLP-1 receptor agonists) target specific areas in the brain to suppress appetite and facilitate weight loss. We also discuss clinical trials data suggesting that these drugs and/or the weight loss that they facilitate may have cardioprotective effects. Lastly, we will also examine evidence regarding weight regain when coming off of these drugs and common side effects.